SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to its FDA-approved drug for a specific type of leukemia, though the drug carries warnings about potentially fatal side effects, leading to concerns about its safety profile.  Despite these concerns, some community members believe the drug's approval doubles its addressable market and view this as a long-term play, while others suggest a potential acquisition. Discussions also include potential market manipulation and the possibility of a short squeeze.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to retail investors targeting a potential short squeeze, evidenced by high borrowing costs and significant social media discussion around depleting float. The community is actively discussing strategies to pressure short sellers, with some users calling for a coordinated effort to recall lent shares. Bullish sentiment seems tied to expectations around insiders increasing their positions.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as analysts are raising price targets, citing increasing DRAM prices and AI demand, with UBS setting a target of $245 and Citi at $240. The community is closely watching for a breakout above $200 and speculating about potential partnerships, particularly with OpenAI, while also weighing its removal from the Chinese server market. Bullish sentiment revolves around Micron's undervalued status compared to its peers and the expectation of strong earnings reports driving further gains.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford's stock is trending downwards as a fire at a key aluminum supplier is expected to disrupt production, particularly for the profitable F-150 trucks. The community is debating whether this dip is an overreaction, a buying opportunity, or a sign of deeper issues with Ford's supply chain management and future guidance. Discussions also involve potential tariff relief and its impact on Ford's financials amid the aluminum shortage.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge potentially fueled by news of insider buying and a milestone payment from Merck related to their Alzheimer's program. The community is actively discussing the low float and potential for a short squeeze, with some speculating about a potential run to double digits. However, some traders caution about potential dilution.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to increased discussion around its progress in quantum computing, particularly error correction, and its potential impact on AI. The community is weighing the significance of IBM's partnerships, like the one with AMD, and debating whether its established position gives it an edge over smaller quantum computing companies. Some are calling IBM undervalued given its free cash flow and position in the quantum computing space.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as the community discusses its continued strength in the semiconductor market, fueled by AI prospects and key partnerships, even amidst concerns of bubble territory. Recent advancements in graphics technologies and speculation around upcoming announcements at the GTC conference are adding to the bullish sentiment. Traders are closely watching for a potential breakout towards the $200 level, while also weighing the impact of broader market factors and potential government actions.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp is trending amid discussions of a potential Newmont takeover of Barrick's Nevada gold assets and Scotiabank upgrading its rating to Sector Outperform. Community members are also discussing the company's solid liquidity and potential merger opportunities. Some are also pointing out recent job cuts with others expecting gold to soar further.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the community discusses potential government investment in the quantum computing sector following recent news, despite some skepticism. Community members are debating the company's valuation and future prospects in light of competition and potential dilution, while also pointing out the CEO's equity stake. Technical traders are watching key price levels for potential breakouts or breakdowns.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as investors discuss its potential breakout past the $55 resistance level, a key price point from its previous earnings gap down. Community members are analyzing chart patterns like inverse head and shoulders, anticipating a move towards $70, while also weighing the impact of potential announcements and broader tech sector momentum. Discussions also include the potential impact of OpenAds and collaborations with companies like OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds

Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Germany-based biotechnology firm BioNTech SE (BNTX) on Thursday said that it intends to acquire its peer CureVac (CVAC) in an all-stock transaction. CVAC stock shot up by about 32% in pre-market trading.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/12/3098162/0/en/BioNTech-Announces-Strategic-Transaction-to-Acquire-CureVac-in-Public-Exchange-Offer.html">deal</a>, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares, resulting in an implied aggregate equity value for CureVac of roughly $1.25 billion.BioNTech also stated that the purchase consideration is subject to a collar mechanism. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.BioNTech will own 100% of CureVac and its subsidiaries, and it will integrate CureVac’s research and manufacturing site in Tübingen.The companies stated that the acquisition will create long-term value for shareholders of both companies and will build on BioNTech’s track record in messenger ribonucleic acid (mRNA) commercialization, including its mRNA-based COVID-19 vaccine developed in collaboration with Pfizer Inc (PFE).CureVac is developing a class of medicines in oncology and infectious diseases based on mRNA. BioNTech said that the transaction will strengthen the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates.The transaction is expected to close in 2025, subject to the completion of customary closing conditions and receipt of regulatory approvals.On Stocktwits, retail sentiment around CureVac jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_42_07_AM_png_e0cc4dfb95.webp" alt="CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="628" height="67"><figcaption>CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, who claims to hold CureVac shares, expressed disappointment, opining that they could have gotten a better deal.<stembedurl>https://stocktwits.com/Jbjb90/message/617662210</stembedurl>Meanwhile, retail sentiment around BioNTech rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:629/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_44_46_AM_png_29640c1cdc.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="629" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the deal might lead to a “breakthrough” in cancer treatment.<stembedurl>https://stocktwits.com/quinny2021/message/617661886</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX</a> is trading 1% higher in pre-market.While BNTX shares are down by about 9% this year, <a href="https://stocktwits.com/symbol/CVAC">CVAC shares</a> are up by about 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-restarts-partial-services-in-china-amid-us-export-curbs/chlXDS8Rb6s">Synopsys Reportedly Restarts Partial Services In China Amid US Export Curbs, But Retail Remains Skeptical</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment

Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.

CureVac stock soars about 30% after BioNTech agrees to acquire co 

Investing.com -- CureVac NV (NASDAQ:CVAC) stock soared 29.5% on Thursday pre-market trading after German biotech firm BioNTech SE (NASDAQ:BNTX) said it would acquire the company for approximately $1.25 billion.

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '23	-$0.24	--	--	N/A
Q2 '23	-$0.26	--	--	N/A
Q1 '23	-$0.35	--	--	N/A

CVAC
CureVac N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '23

Historical Earnings

Latest CVAC News

CVACCureVac N.V.